New role of extemporaneous manufacturing in regulating drug products access onto the market

The aim of the work was to study the legal aspects of the legislative regulation for manufacturing medicines in a pharmacy organization.

Materials and methods. Databases of ConsultantPlus, Cyberleninka, Food and Drug Administration (FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), PubMed, e-library, WIPO Lex were used as search sources. The search was based on the following keywords and phrases: intellectual property, pharmacies+invention, patent, drugs, extemporal+production, orphan+diseases, as well as their Russian counterparts. 133 sources of information, including scientific articles and regulations, were found out; 50 have been included in this review. The analysis of information sources published from 2013 to 2023, was determined by the peculiarities of legislation changes in this area.

Results. The article provided an overview of modern, including regulatory practice, pharmaceutical manufacturing in the Russian Federation, and also analyzed the benefits of this activity for the medical community, patients and the state. At the same time, the individualization of drug treatment has made it possible to work out systemic solutions for developing drug therapy methods for special groups of patients for whom the economic feasibility of a pharmaceutical registration and launching such drugs onto the market has been brought into challenge. In addition, pharmacy manufacturing is an accessible tool in the study of the drugs prescribed by a doctor not in accordance with the instructions for medical use (off-label) or in the dosage forms/dosages that are not on the market. Extemporaneous manufacturing can be also a part of the process of “repositioning” drugs on the market, subject to compliance with the requirements for pharmacy manufacturing and control of the prescribed drugs safety. The possibility of pharmaceutic drug manufacturing also makes it possible to partially resolve issues related to intellectual property. As a result of the carried out analysis, the following hypothesis was confirmed: the legislative changes have a similar legal assessment both in Russia and abroad and correspond to the legal practice in resolving intellectual property issues in relation to pharmacy organizations.

Conclusion. The renewal of a pharmacy production will improve the availability of the drug care to the population, taking into account individual dosages and dosage forms in various therapeutic areas, and can also become a tool for repositioning drugs or clinical testing of new molecules for rare incurable diseases.

1. Belyatskaya AV, Krasnyuk II, Krasnyuk II, Stepanova OI, Korol LA, Rastopchina OV. Usage of finished dosage forms in the manufacture of extemporaneous powders. Drug development & registration. 2017;(1):82–5. Russian

2. Rodionova I, Ovtcharov E. Pharmaceutical industry of Russian Federation. RUDN Journal of Economics. 2001:(1(7)):70–9. Russian

3. Zatravkin S.N., Vishlenkova E.A., Ignatiev V.G. The Russian pharmaceutical branch in 1990s. Report 1. From the Soviet to the market // Problems of Social Hygiene, Public Health and History of Medicine. – 2022. – Vol. 30. – Nо. 1. – P. 160–66. DOI: 10.32687/0869-866X-2022-30-1-160-166

4. Radnaeva SE, Matskevich IV, Ukhakshinova EM. Pharmaceutical industry in Russia: Analysis AND economic aspects of development. BSU bulletin. Economy and Management. 2020;(3):31–40. DOI: 10.18101/2304-4446-2020-3-31-40

5. Moroz TL, Ryzhova OA. Problems in drug provision for prevention and treatment facilities due to a reduction of intra-pharmacy preparation of medicines. Remedium. 2015;(1-2):43–6. Russian

6. Moroz TL, Ryzhova OA. The problem of the availability of intra-pharmaceutical drugs (on the example of the Irkutsk region). REMEDIUM. 2020;(10):54–7. Russian

7. Lin AA, Sokolov BI, Slepnev DM. Pharmaceutical market: medicine production in Russia. Problems of modern economics. 2013;1(45):191–5. Russian

8. Vatanskaya OA, ZHidkova YuYu, Enikeeva RA. Practical importance of extemporal recipe in modern pharmaceutical practice. Russian Military Medical Academy Reports. 2020;39(S3-4):23–7. Russian

9. Kiseleva LG. Problems and prospects of intra-pharmacy manufacturing of medicinal preparations. Rostov Scientific Bulletin. 2021;(5):46–8. Russian

10. Egorova S.N. Can a medical organization do without extemporal medicines? Modern drug supply organization. 2021;8(1):42–6. DOI: 10.30809/solo.1.2021.11. Russian

11. Abrosimova NV, Kryukova IV. Providing the population of the far eastern federal district with pharmacy made medications: problems and trends. Public Health of the Far East. 2022;3(93):44–8. DOI: 10.33454/1728-1261-2022-3-44-48. Russian

12. Ryabova EI, Guseva OL, Ryabova EV. On the relevance of manufacturing extemporal dosage forms in a multi-specialty hospital pharmacy. Modern drug supply organization. 2021;8(1):80–2. DOI: 10.30809/solo.1.2021.26. Russian

13. Smekhova IYe, Ladutko YuM, Kalinina OV. Extemporal manufacture of medicines. problems and solutions. Vestnik farmacii. 2021;1(91):48–52. DOI: 10.52540/2074-9457.2021.1.48. Russian

14. Narkevich IA, Nemyatykh OD, Medvedeva DM, Smekhova IE, Ladutko YuM, Strelkov SV. Organizational and pharmaceutical aspects of improving medicinal provision of children (on the example of St. Petersburg). Journal of Siberian Medical Sciences. 2020;(1):31–43. DOI: 10.31549/2542-1174-2020-1-31-43

15. Egorova SN, Kondakov SE, Gordeev VV, Belezky SO, Hayatov AR, Ikhalaynen ES. Recent problems of children pharmaceutical dosage formulation in russian federation. Vestnik of Smolensk State Medical Academy. 2019;18(4):220–28. Russian

16. Korol LA, Egorova SN, Kudlay DA, Krasnyuk II, Sologova SS, Korol VA, Smolyarchuk EA, Sadkovskii IA, Mandrik MA. Modern extemporaneous formulations in the geriatric care management: current opportunities and future challenges. A review. Terapevticheskii Arkhiv. 2022;94(8):1020-27. DOI: 10.26442/00403660.2022.08.201805. Russian

17. Tarabukina SM, Dremova NB. The problem of manufacturing “off-label” medicines in a hospital pharmacy. Modern organization of drug supply. 2021;8(1):106–8. DOI 10.30809/solo.1.2021.36. Russian

18. Egorova SN, Khayatov AR, Shavaliev RF. Promises for transfer of an ex tempore baby formula to commercial production. Pharmacy. 2014;(2):28–31. Russian

19. Brion F, Nunn AJ, Rieutord A. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals. Acta Paediatr. 2003 Apr;92(4):486–90. DOI: 10.1111/j.1651-2227.2003.tb00583.x

20. Saito J, Akabane M, Ishikawa Y, Iwahashi K, Nakamura H, Yamatani A. Retrospective survey of compounded medications for children in Japan. Eur J Pharm Biopharm. 2020 Oct;155:122–7. DOI: 10.1016/j.ejpb.2020.08.016

21. Dooms M. Pharmacists are initiators in palliative care for patients with rare diseases. Orphanet J Rare Dis. 2023 Jun 8;18(1):141. DOI: 10.1186/s13023-023-02765-8

22. Polak Y, Jacobs BAW, Kemper EM. Pharmacy Compounded Medicines for Patients With Rare Diseases: Lessons Learned From Chenodeoxycholic Acid and Cholic Acid. Front Pharmacol. 2021 Sep 28;12:758210. DOI: 10.3389/fphar.2021.758210

23. Haznar-Garbach D, Garbacz G, Weitschies W. Development of oral foams for topical treatment of inflammatory bowel disease. Journal of Drug Delivery Science and Technology. 2019;(50):87–292. DOI: 10.1016/j.jddst.2019.01.022

24. Hendrickx K, Dooms M. Orphan Drugs, Compounded Medication and Pharmaceutical Commons. Front Pharmacol. 2021 Sep 10;12:738458. DOI: 10.3389/fphar.2021.738458

25. Malchenkova SS, Golyak NS. Current status of extemporal production of medicines in the federal republic of Germany. Vestnik Farmacii. 2022;3(97);44–56.

26. DOI: 10.52540/2074-9457.2022.3.44. Russian

27. Oborin MS. Problems and prospects of import substitution in the pharmaceutical industry of the region. Scientific Bulletin: Finance, Banking, Investment. 2020;3(52):185–94. Russian

28. Saleniece I, Korcagina L, Krigere Kr, Vrublevska R, Muceniece R. Studies on extemporal drug storage and expiration dates. European Journal of Pharmaceutical Sciences. 2007;32(1):24–5. DOI: 10.1016/j.ejps.2007.05.0515

29. Kuhach VV. Pharmacy manufacture and quality control of medicinal preparations abroad. Vestnik Farmacii. 2021;2(92):64–79. DOI: 10.52540/2074-9457.2021.2.64

30. Petrov AYu, Airo IN, Berezhnaya ES, Kinev MYu, Goncharova YuM. Problems of extemporal manufacture of dosage forms in pharmacy organizations as a form of personalized pharmacy in the Russian Federation and abroad. Medicine. Sociology. Philosophy. Applied Research. 2022;(6):77–84. Russian

31. MacArthur RB, Ashworth LD, Zhan K, Parrish RH 2nd. How Compounding Pharmacies Fill Critical Gaps in Pediatric Drug Development Processes: Suggested Regulatory Changes to Meet Future Challenges. Children (Basel). 2022 Dec 1;9(12):1885. DOI: 10.3390/children9121885

32. Timko RJ, Crooker PE. Pharmaceutical compounding or pharmaceutical manufacturing? A regulatory perspective. Int J Pharm Compd. 2014 Mar-Apr;18(2):101–11.

33. Minghetti P, Pantano D, Gennari CG, Casiraghi A. Regulatory framework of pharmaceutical compounding and actual developments of legislation in Europe. Health Policy. 2014 Sep;117(3):328–33. DOI: 10.1016/j.healthpol.2014.07.010

34. Uriel M, Marro D, Gómez Rincón C. An Adequate Pharmaceutical Quality System for Personalized Preparation. Pharmaceutics. 2023 Mar 1;15(3):800. DOI: 10.3390/pharmaceutics15030800

35. Blinova MP, Ilina TYu, Kotova NI, Krishtanova NA, Podushkin VYu. Kontrol’ kachestva lekarstvennyh sredstv aptechnogo izgotovleniya – sovremennoe sostoyanie i perspektivy razvitiya [Quality control of pharmacy drugs – current state and development prospects]. Innovations in the health of the nation: collection of materials of the III All-Russian scientific and practical conference with international participation, St. Petersburg, November 10–11, 2015; St. Petersburg: St. Petersburg State Chemical Pharmaceutical Academy, 2015, 12–15 p. Russian

36. Carvalho M, Almeida IF. The Role of Pharmaceutical Compounding in Promoting Medication Adherence. Pharmaceuticals (Basel). 2022 Aug 31;15(9):1091. DOI: 10.3390/ph15091091

37. Vanhoorne V, Peeters E, Van Tongelen I, Boussery K, Wynendaele E, De Spiegeleer B, Remon JP, Vervaet C. Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases. Orphanet J Rare Dis. 2019 Aug 1;14(1):186. DOI: 10.1186/s13023-019-1154-x

38. Rosenberg N, van den Berg S, Stolwijk NN, Jacobs BAW, Post HC, Pasmooij AMG, de Visser SJ, Hollak CEM. Access to medicines for rare diseases: A European regulatory roadmap for academia. Front Pharmacol. 2023 Feb 28;14:1142351. DOI: 10.3389/fphar.2023.1142351

39. Watson CJ, Whitledge JD, Siani AM, Burns MM. Pharmaceutical Compounding: a History, Regulatory Overview, and Systematic Review of Compounding Errors. J Med Toxicol. 2021 Apr;17(2):197–217. DOI: 10.1007/s13181-020-00814-3

40. Narkevich IA, Golant ZM, Yurochkin DS, Leshkevich AA, Erdni-Garyaev SE. Development of proposals for improving the processes of circulation of extemporal drugs and regulation of prescription and production activities of pharmaceutical organizations in the Russian Federationю REMEDIUM. 2021;(4):14–29. DOI: 10.32687/1561-5936-2021-25-4-14-29

41. Tarasova EN, Kolkov MA. Ispol’zovanie gotovyh lekarstvennyh form pri izgotovlenii ekstemporal’nyh lekarstvennyh sredstv [The use of finished dosage forms in the manufacture of extemporaneous medicines]. Sander Readings: Collection of materials of the conference dedicated to the memory of the outstanding domestic scientist in the field of drug technology Yuri Karlovich Sander, St. Petersburg, January 27, 2023; St. Petersburg: St. Petersburg State Chemical and Pharmaceutical University, 2023, 82-86 p.

42. Kuz’mina AV, Asetskaya IL, Polivanov VA, Zyryanov SK. Medication errors associated with carbapenems. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2016;(4):48–53. Russian

43. Padhy BM, Gupta YK. Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med. 2011 Apr-Jun;57(2):153–60. DOI: 10.4103/0022-3859.81870

44. Pelyushkevich AV, Sineva TD, Alekseeva GM, Karavaeva AV. Extemporaneous dosage forms for children: prospects and ways of improvement. Medicine: Theory and Practice. 2019;4(S):420–1. Russian

45. Telnova E, Zagoruychenko A. Pharmaceutical substances for industry and industrial pharmacies. Problems and prospects for solutions. New Pharmacy. 2021;(5)34–41. Russian

46. Alexandrovich YuS, Pshenisnov KV, Felker EYu, Abramova NN, Gabrusskaya TV. Urea Cycle Defects Causing Acute Cerebral Failure in Children: case report. Annals of Critical Care. 2017;(1):74–80. DOI: 10.21320/1818-474X-2017-1-74-80. Russian

47. Moloney K. The New Role of the Patented Medicine Prices Review Board (PMPRB). McGill Journal of Law and Health. 2023;2 Blog.

48. Kusmaeva GI. The analysis of legal regulation of advertising of extemporal medicines. Dnevnik Nauki. 2021;8(56):1–6. Russian

49. Galkowskaya VG, Lyskova NB, Polyakova AA, Krivoruchko TE. Applications for inventions relating to derivatives of known substances: a new perspective. Patents and Licenses. Intellectual Rights. 2019;(8):24–37. Russian

50. Gavrilova EB, Lyskov NB. About patenting of medicines. Patents and Licenses. Intellectual Rights. 2019;(3):13–20. Russian

51. Kuznetsova EYu, Ovchinnikova PP, Semencheva AS. The problem of applying “off-label” medication in Russia. International Research Journal. 2020;9(99):133–8. DOI: 10.23670/IRJ.2020.99.9.022. Russian